{'fraction_non_alphanumeric': 0.0291005291005291, 'fraction_numerical': 0.003968253968253968, 'mean_word_length': 5.699115044247788, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Correction by nicotinamide and nicotinoyl-GABA of dopamine metabolism in rat brain in experimental Parkinson's disease].

It was established, that serotonin and dopamine content and dopamine uptake by brain nerve endings under experimental parkinsonism are decreased. Nicotinamide nicotinoyl-GABA administration leads to normalization these parameters. It was shown that NAm was more effective on serotonin content while nicotinoyl-GABA on dopamine one. Dopamine uptake was impaired at experimental parkinsonism and partially was normalized by incubation with NAD (10(-6) M). Thus, NAm, nicotinoyl-GABA and NAD are involved in the regulation of brain neurotransmission under experimental parkinsonism and can be useful in treatment of Parkinson's disease.